HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2016

  • ID: 3802749
  • Company Profile
  • 46 pages
  • Global Markets Direct
1 of 3
HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2016

Summary

‘HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the HanAll Biopharma Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by HanAll Biopharma Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of HanAll Biopharma Co., Ltd.
- The report provides overview of HanAll Biopharma Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses HanAll Biopharma Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features HanAll Biopharma Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate HanAll Biopharma Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for HanAll Biopharma Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding HanAll Biopharma Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables

List of Figures

HanAll Biopharma Co., Ltd. Snapshot

HanAll Biopharma Co., Ltd. Overview

Key Information

Key Facts

HanAll Biopharma Co., Ltd. - Research and Development Overview

Key Therapeutic Areas

HanAll Biopharma Co., Ltd. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

HanAll Biopharma Co., Ltd. - Pipeline Products Glance

HanAll Biopharma Co., Ltd. - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

HanAll Biopharma Co., Ltd. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

HanAll Biopharma Co., Ltd. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

HanAll Biopharma Co., Ltd. - Drug Profiles

(atorvastatin calcium + losartan potassium)

Product Description

Mechanism of Action

R&D Progress

(amlodipine besylate + candesartan cilexetil)

Product Description

Mechanism of Action

R&D Progress

(chlorthalidone + telmisartan)

Product Description

Mechanism of Action

R&D Progress

cobamamide

Product Description

Mechanism of Action

R&D Progress

HL-143

Product Description

Mechanism of Action

R&D Progress

(candesartan cilexetil + metformin hydrochloride)

Product Description

Mechanism of Action

R&D Progress

HL-036

Product Description

Mechanism of Action

R&D Progress

somatropin

Product Description

Mechanism of Action

R&D Progress

HL-156FIB

Product Description

Mechanism of Action

R&D Progress

HL-161

Product Description

Mechanism of Action

R&D Progress

HL-176

Product Description

Mechanism of Action

R&D Progress

HL-178

Product Description

Mechanism of Action

R&D Progress

HL-271

Product Description

Mechanism of Action

R&D Progress

HanAll Biopharma Co., Ltd. - Pipeline Analysis

HanAll Biopharma Co., Ltd. - Pipeline Products by Target

HanAll Biopharma Co., Ltd. - Pipeline Products by Route of Administration

HanAll Biopharma Co., Ltd. - Pipeline Products by Molecule Type

HanAll Biopharma Co., Ltd. - Pipeline Products by Mechanism of Action

HanAll Biopharma Co., Ltd. - Recent Pipeline Updates

HanAll Biopharma Co., Ltd. - Dormant Projects

HanAll Biopharma Co., Ltd. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

HL-015

HL-016

Loratadine ODT

HanAll Biopharma Co., Ltd. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 46List of Tables

HanAll Biopharma Co., Ltd., Key Information

HanAll Biopharma Co., Ltd., Key Facts

HanAll Biopharma Co., Ltd. - Pipeline by Indication, 2016

HanAll Biopharma Co., Ltd. - Pipeline by Stage of Development, 2016

HanAll Biopharma Co., Ltd. - Monotherapy Products in Pipeline, 2016

HanAll Biopharma Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016

HanAll Biopharma Co., Ltd. - Pre-Registration, 2016

HanAll Biopharma Co., Ltd. - Phase III, 2016

HanAll Biopharma Co., Ltd. - Phase II, 2016

HanAll Biopharma Co., Ltd. - Phase I, 2016

HanAll Biopharma Co., Ltd. - Preclinical, 2016

HanAll Biopharma Co., Ltd. - Pipeline by Target, 2016

HanAll Biopharma Co., Ltd. - Pipeline by Route of Administration, 2016

HanAll Biopharma Co., Ltd. - Pipeline by Molecule Type, 2016

HanAll Biopharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2016

HanAll Biopharma Co., Ltd. - Recent Pipeline Updates, 2016

HanAll Biopharma Co., Ltd. - Dormant Developmental Projects,2016

HanAll Biopharma Co., Ltd. - Discontinued Pipeline Products, 2016

HanAll Biopharma Co., Ltd., Other Locations 44List of Figures

HanAll Biopharma Co., Ltd. - Pipeline by Top 10 Indication, 2016

HanAll Biopharma Co., Ltd. - Pipeline by Stage of Development, 2016

HanAll Biopharma Co., Ltd. - Monotherapy Products in Pipeline, 2016

HanAll Biopharma Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016

HanAll Biopharma Co., Ltd. - Pipeline by Top 10 Target, 2016

HanAll Biopharma Co., Ltd. - Pipeline by Route of Administration, 2016

HanAll Biopharma Co., Ltd. - Pipeline by Molecule Type, 2016

HanAll Biopharma Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll